SonoGen (QW7437) is an anionically charged 2% perfluorocarbon emulsion under development as a transpulmonary myocardial ultrasound contrast agent (UCA). The SonoGen microbubbles have a reduced adherence to the negatively charged vascular endothelium and reduced coalescence. SonoGen, a second generation USCA has the theoretical potential to provide high safety and efficacy and improved tissue grayscale persistence compared to first generation fluorocarbon contrast agents.

The third generation ultrasound contrast agents (UCA/USCA) are more echogenic and stable, and are able to enhance the echogenicity of parenchyma on B-mode images. These microbubbles may thus show perfusion, even in such a difficult region as the myocardium.

See also History of Ultrasound Contrast Agents.

In 3D ultrasound (US) several 2D images are acquired by moving the probe across the body surface or rotating inserted probes. 3D-mode uses the same basic concept of a 2D ultrasound but rather than take the image from a single angle, the sonographer takes a volume image. The volume image that is displayed on the screen is a software rendering of all of the detected soft-tissue combined by specialized computer software to form three-dimensional images.
The 3D volume rendering technique (VR) does not rely on segmentation (segmentation techniques are difficult to apply to ultrasound pictures) and makes it possible to obtain clear 3D ultrasound images for clinical diagnosis. A 3D ultrasound produces a still image. Diagnostic US systems with 3D display functions and linear array probes are mainly used for obstetric and abdominal applications. The combination of contrast agents, harmonic imaging and power Doppler greatly improves 3D US reconstructions.

3D imaging shows a better look at the organ being examined and is used for:

Fusion 3D imaging methods for generating compound images from two sets of ultrasound images (B-mode and Doppler images) enable the observation of the structural relationships between lesions and their associated blood vessels in three dimensions (maximum intensity projection).

[This entry is marked for removal.]

Amersham Health, now GE Healthcare was the imaging diagnostics and therapy business of Amersham plc. The imaging business produced contrast agents that are injected into the body to improve pictures obtained through medical imaging scans.

From Bracco Research S. A., Geneva, Switzerland
BG1135 is a polymer-shelled new ultrasound contrast agent under development. The air-filled microsphere has a rigid, 100 nm thick polymeric shell and a mean diameter of 2.9 μm with 99% less than 8 μm.
The destruction mechanism of BG1135 is unique among microbubbles. The microbubbles of BG1135 appear to acquire a small shell defect, allowing the filling gas to stream out and creating a new gas bubble, but leaving the old shell intact. No significant differences between the diameters of the shells can be measured before and after insonation even though the agent is fragmented.